Onyx Pharmaceuticals Inc (ONXX)

[surf1944]

2:37AM Onyx Pharma: Ph. 3 trial of Nexavar in first-line advanced non-small cell lung cancer does not meet primary endpoint of overall survival (ONXX) 22.83 : Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announce that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting. NExUS evaluated Nexavar versus placebo in combination with two chemotherapeutic agents, gemcitabine and cisplatin. A positive secondary endpoint of progression-free survival was observed in the trial. The safety and tolerability of the treatment triplet was as expected and did not show any new or unexpected toxicities. Data from this study are expected to be presented at an upcoming scientific meeting. Co will host a teleconference and webcast on Monday, June 14, 2010, at 9:00 AM EST to provide an update on Nexavar tablets.